Dexapos eye drops 1 mg/ml, 5 ml — Made in Germany by Ursapharm — Free Delivery

Product description

Dexapos eye drops are indicated in the treatment of severe inflammation of the eye of non-infectious origin, such as severe allergic eye diseases, severe inflammation of the conjunctiva, cornea and anterior segment of the eye, as well as inflammation in the postoperative period.

Structure

Active substance: dexamethasone;

1 ml 1 mg dexamethasone sodium metasulfobenzoate;

Excipients: thiomersal, hypromellose, glucose monohydrate, water for injection.

Contraindications

• hypersensitivity to the active substance or to any excipients of the preparation;
• viral, bacterial, or fungal infections of the eye;
• corneal trauma or ulcers;
• glaucoma;
• immunosuppressive conditions.

Mode of application

The preparation is intended for ophthalmic use.

The preparation is instilled into the conjunctival sac of the affected eye 1 drop 3-5 times a day. In accordance with the doctor's prescription, in case of especially severe acute conditions, at the beginning of treatment, dexapos can be instilled more often.

Usually, the course of treatment should not exceed 2 weeks. If no improvement is observed after the first 2 days of treatment, the advisability of further therapy should be re-evaluated.

When instilling eye drops, avoid any contact of the dropper tip with the eye or skin.

Application features

Pregnant

Not recommended for use during pregnancy.

Children

Not for use in children.

Drivers

Carefully.

Overdose

Possible clinical signs and symptoms of overdose (punctate keratitis, erythema, increased lacrimation, edema and itching of the eyelids) may be similar to adverse reactions that have been observed in some patients. Long-term intensive use can lead to systemic side effects.

In case of an overdose with topical application, wash the excess of the preparation from the eye (s) with warm water. Treatment is symptomatic.

Side effects

The most common side effects that were observed during clinical trials of the preparation Dexapos were discomfort in the eye, keratitis and eye irritation, occurred in 0.7 - 0.9% of patients.

Interaction

Concomitant administration of topical steroids and topical non-steroidal anti-inflammatory preparations (NSAIDs) may increase the risk of complications during corneal wound healing.

CYP3A4 inhibitors (including ritonavir and cobicistat) may decrease the clearance of dexamethasone and increase the adrenal suppressive effect / Cushing's syndrome. Such combinations should be avoided unless the benefit outweighs the risk of an increase in systemic side effects of GCS, in this case, careful monitoring of the systemic effects of GCS should be carried out.

In the case of concomitant therapy with the use of other local ophthalmic preparations, an interval of 10-15 minutes should be observed between their instillation. Eye ointments should be used last.

Storage conditions

Store in its original packaging at a temperature not exceeding 25 ° C.

Keep out of the reach of children.

Shelf life is 2 years.